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Abstract
Objective The purpose of this study was to draw up two protocols designed to help Maltese
pharmacists care for consumers seeking treatment for headache and back pain and to
subsequently use the protocols to assess pharmacists’ management of the named conditions.
Method The setting was a sample of 10 of the 207 community pharmacies in Malta. Two
flow-chart protocols for headache and back-pain management were developed from various
reference sources. The protocols were first tested in a community pharmacy for practicality
and applicability in a pilot study. In nine other pharmacies chosen at random the pharmacists’
manner of addressing 10 headache and 10 back-pain cases in each pharmacy was compared
with that recommended in the protocols. Consumers who visited the pharmacy to fill a
prescription, to purchase a named product or for advice on how to deal with symptoms were
included in the study.
Key findings Of the 212 pharmacist interventions assessed, cases where pharmacists
responded to symptoms were managed with the highest average compliance (57%) whereas
cases in which the consumer asked for a product by name were managed with an average
compliance with the protocols of 46%. Cases in which consumers presented at the pharmacy
with a prescription were managed with an average compliance of 55%.
Conclusions Protocols may be used as a means of measuring the impact of the intervention
of community pharmacists in patient care. The findings suggest a lack of advice given to
consumers presenting at the pharmacy to request a named product.
Keywords back pain; community pharmacy; headache; protocols
Introduction
The intervention of community pharmacists in responding to consumers with minor
ailments continues to be one of the major contributions by community pharmacists to the
maintenance of the best health possible for their society.[1] The demand for primary care in
a community pharmacy setting is on the increase[2–4] and is associated with a number of
factors, including the need for medicines, patient perceptions of pharmacists’ healthcare
role and the nature of the presenting condition; indeed, symptoms of minor self-limiting
conditions are usually given as the main reason for using a pharmacy.[5]
With more than 90% of the population experiencing one or more headaches in their
lifetime[6,7] and approximately 80% of adults experiencing low back pain that will affect
their daily activities at some point in their lives,[8] the community pharmacist is often
approached with regards to advice for and treatment of these conditions.[9] With 66% of
patients who take medications for headache actually buying these from a pharmacy[10] and
back pain identified as one of the most common complaints pharmacists hear from patients
seeking advice and over-the-counter pain relief,[11,12] self-medication seems to be the main
method of treatment. Headache and back pain were thus considered ideal topics for protocol
development since pharmacists are in an ideal place to provide advice for these conditions and
help improve patient care.
The identification and addressing of patients’ needs and concerns by community
pharmacists has, however, been shown to be variable.[13,14] With protocols, pharmacists are
assisted in the decision-making process of responding to symptoms, recommended treatment
choices are evidence-based and patient outcomes improved.[15,16] A protocol is defined as a
disease-based therapeutic algorithm, which begins with a confirmed diagnosis of a particular
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disease and directs the healthcare provider through a series
of decisions that differentiate patients into alternative
pathways.[17]
Notwithstanding the advantages of protocols, little work on
their development and use has been carried out in Malta. In
Malta, the availability of over-the-counter medicines is limited
to pharmacies and no other retail outlet. There is on average
one community pharmacy for every 2000 persons. Pharmacies
have only one pharmacist on duty at a particular time. Other
pharmacists replace the managing pharmacist on a part-time
basis. This results in 44% of Maltese pharmacists contributing
to the profession through pharmacy practice.[18] Seventy seven
per cent of pharmacies employ one or more pharmacy
technicians or salespersons or both.[1] There is no requirement
for salespersons to hold a minimum qualification to work in
pharmacies. Pharmacy technicians may dispense medicinal
products only under the supervision of a pharmacist.
The purpose of this study was thus to develop flow-chart
headache and back-pain protocols to be used in the community
pharmacy setting. The protocols were intended to act as a
guideline by highlighting a specific plan according to which
the condition of the patient was best managed. The protocols
were subsequently used in a pilot study to test their practicality
and applicability in the community pharmacy setting. A final
goal was to use the protocols as a means of evaluating
pharmacists’ interventions according to the manner in which
patients were questioned, advice given and treatment
recommended.
Method
Protocol design
Two flow-chart protocols, for headache and back-pain manage-
ment, were developed using key pharmacy journals, standard
textbooks and other references. The format selected for the
presentation of the protocols was that used by the American
Pharmaceutical Association (APhA),[17] which translates the
information into a flow chart, deemed ideal for succinctly
conveying the relationship and sequential direction of steps.
Each protocol included the following. (1) Questions about
patient identity as well as the duration, location, intensity and
type of pain: this type of specific information about the person
requiring treatment is essential for the pharmacist. (2) A one-
page diagram, termed the prescription sheet, which contained
the series of steps to be followed when the pharmacist was
presented with a prescription. (3) Statements detailing the most
encountered headache or back-pain conditions. These state-
ments were designed to distinguish between the different
conditions on the basis of the different accompanying
symptoms and trigger factors. For example, the constricting
band of pain felt around the head when a patient is under stress,
typical of a tension headache, helps to differentiate it from the
dull pain and tenderness around the eyes and cheekbones
accompanied by a blocked nose, typical of sinusitis.[19,20] The
diagnosis ends with a decision of whether to treat or refer the
patient. (4) A treatment sheet which outlined the management
of the condition, including non-pharmacological measures and
over-the-counter pharmacological treatment. (5) An explana-
tory text, the main purpose of which was to present the
background information and references to support information
in the flow charts.
Evaluation of the protocols
Qualitative validity, applicability and practicality testing were
employed. To assess validity of the protocols, two general
practitioners and two pharmacists were approached. The aims
of the study were outlined. Meetings were held with each to
review content validity of the protocols. The length of the
protocol was questioned; however, it was agreed to retain all
areas so as to present a comprehensive overview of both
conditions. Applicability and practicality of the protocols were
assessed through a pilot test. The researcher visited one
community pharmacy, chosen for convenience, to ascertain
that the protocols were acceptable for use in the practical
setting and that it was feasible to use the protocols to assess
pharmacists’ interventions through observation. The pilot
study also helped determine whether 10 cases were likely to
be collected within the set time frame and how long data
collection was likely to take. The documentation form was
also reviewed to check its adequacy for recording the
necessary information. Results from this pharmacy were
included in the final analysis since the minor changes made to
the protocols still permitted the grouping of data.
Assessing pharmacists’ interventions
For the assessment of pharmacists’ interventions using the
protocols, the non-participant observation technique was
adopted since it is simple and feasible to perform within the
environment of a community pharmacy when compared to
other documentation techniques.[1] It does not rely on a
consumer’s disposition to respond to questions or ability to
recall events (as opposed to self-completed questionnaires),
and avoids eligible consumers not participating during times
when the pharmacy is particularly busy or short of staff
(reasons for non-recruitment by pharmacists).[21]
Nine pharmacies were chosen at random (from a list of all
pharmacies in Malta), in which to perform the research. This
brought the total number of pharmacies to 10 since pilot data
collected from the first pharmacy were also included in the
final analysis. The managing pharmacists were contacted and
informed of the aims of the study. The dates and times of
each observation session were agreed.
During the first observation session in each pharmacy,
pharmacists went through the protocols and gave their
feedback. Each pharmacy was then attended for the length
of time required to document pharmacists’ interventions in
10 headache and 10 back-pain cases. A record was also kept
of the total number of consumers walking into the pharmacy
during the observation sessions.
Consumers visiting a pharmacy have a number of options
when presenting with a minor condition.[22] For the purposes
of this study, all pharmacist interventions were placed in
three categories. Cases where consumers presented at the
pharmacy to fill a prescription were termed Prescription
cases. Those cases where consumers requested a product by
name were classified as Specific product cases and those
cases where consumers frequented the pharmacy for advice
on how to deal with symptoms were designated as Describing
symptoms cases. The inclusion criterion for these three
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categories was that there had to be some exchange of
information between consumer and pharmacist, allowing the
observer to identify the case as being pertinent to the study.
Data for each case were recorded on a documentation
form. In the first column, the observer ticked the steps from
the protocol which were followed by the pharmacist during
the management of a particular case. In a second column,
the observer ticked all the steps which should have been
followed according to the protocol. By comparing the
divergence between the two sets of data the pharmacist’s
compliance with the protocol for each case was calculated.
For the purpose of the study compliance was defined as ‘a
measure of the extent to which the pharmacist’s behaviour
matched the recommendations in the protocols’.[23]
Ethical approval was not required for the purposes of this
study, since no patient data were recorded. Only pharmacists
who consented to participate in the study and their manage-
ment of headache and back-pain cases were observed.
Results
Response rate and demographics
Nine pharmacists out of the 10 contacted agreed to take part in
the study. One pharmacist refused to participate, claiming
restrained space in the pharmacy. Another pharmacy was
chosen at random instead. Of the pharmacies recruited to take
part in the study, three were in the Southern Harbour district,
two in the Northern Harbour district, one in the Western
District, and four in the Northern District. Two districts – the
South-Eastern District and Gozo (geographically isolated) –
were not represented. The mean population per pharmacy was
1912. In these pharmacies only one pharmacist was in
attendance at any one time. Salespersons were absent in three
pharmacies, all three owned by a pharmacist. Five pharmacies
had one salesperson and two pharmacies had two and three
salespersons respectively. An estimated 21 consumers per hour
visited the pharmacies.
The protocols
This study set out to draw up two protocols based on two
conditions commonly present in primary care: headache and
back pain. One hundred and fourteen steps were set up to
diagnose and manage the different headache conditions while
89 steps made up the back-pain protocol. Figure 1 shows an
excerpt from the headache protocol. In Box 1, a consumer
presents at the pharmacy with a complaint of headache. Box 2
establishes whether the pharmacist is familiar with the
consumer, in which case the pharmacist is directed to Box 4.
If the person presenting at the pharmacy is a new consumer,
the pharmacist is directed to Box 3 where questions are asked
about the patient’s identity. In Boxes 4 and 5 the pharmacist
asks about the duration and location of pain. These boxes refer
the pharmacist to the explanatory text where more detail can
be found.
Validity, applicability and practicality
Content validity of the two protocols was found to be strong.
Statements in the protocol were clear and comprehensive.
During the pilot test, the protocols were found to be: detailed
and comprehensive to diagnose and manage the different
headache and back-pain conditions encountered in the
community pharmacy setting; uncomplicated to follow with
an evident layout of information flow; and able to be used as
a means of assessing pharmacists’ interventions in the
management of headache and back-pain disorders.
Interventions
A total of 212 pharmacist interventions were assessed in
the 182 observation hours spent at the 10 participating
pharmacies. All cases were managed with an average
compliance of 52% (range 6–100%). Figure 2 graphically
portrays the percentage compliance of all the recorded cases
with the respective protocols.
Describing symptoms cases accounted for almost half of
the total cases (42%, n = 90 cases). Theyweremanagedwith an
average compliance of 57% (range 6–100%). Prescription cases
(n = 63 cases) made up a further 30% of the total. They were
managed with an average compliance of 55% (range 29–94%).
Specific product cases (n = 59 cases) were the least encoun-
tered, with 28% of the total cases. They were managed with an
average compliance of 41% (range 10–90%).
Headache protocol
The average compliance for the 109 headache cases was 52%
(range 6–100%).
Describing symptoms cases (n = 57 cases) accounted for
more than half of the total headache cases. They were managed
with an average compliance of 56% (range 6–100%). Only one
case was managed with 100% compliance to the headache
protocol. There were 18 cases managed with a compliance
higher than 70%.
Headache Prescription cases were the least encountered,
making up 20% (n = 22 cases) of all headache cases. The
average compliance was 53% (range 29–75%). Only five
cases were managed with a compliance higher that 70%.
Pharmacist asks
about duration of
headache.
Patient presents
with complaint
of headache.
Pharmacist
familiar with
patient?
Pharmacist asks
about location of
pain.
Pharmacist asks
questions to know
identity of patient.
Go to Box 4 
See text.
Go to Box 5
See text.
Go to Box 6
1
2
3
4
5
Yes
No
Yes
Yes
Figure 1 Excerpt from the headache protocol
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The 28% (n = 30 cases) of headache cases classified as
Specific product cases had the lowest average compliance of
46% (range 14–90%). Only four cases were managed with a
compliance higher than 70%.
The most commonly presented headaches were those as
part of cold symptoms, which added up to 19% of all cases
(n = 21 cases). These were followed by tension headaches
(n = 18 cases), sinus headaches (n = 16 cases) and migraine
headaches (n = 15 cases). There were four cases in which the
headache was thought to be drug-induced. In 11% of cases
(n = 12 cases) the pharmacist did not establish the type of
headache or the circumstances that caused it. These were
mostly cases where the consumer requested a named product.
The most commonly dispensed medications were para-
cetamol, ibuprofen and combination products, which con-
tained paracetamol, ibuprofen, aspirin, caffeine, codeine (up to
12.5 mg per tablet), antihistamines and nasal decongestants.
Back-pain protocol
The average compliance for the 103 back-pain cases
collected was 52% (range 10–94%).
The 32% (n = 33 cases) of back-pain cases placed in the
Describing symptoms category had an average compliance of
59% (range 10–93%). There were 13 cases managed with a
compliance higher than 70%.
Back-pain Prescription cases were the most encountered,
making up 40% (n = 41 cases) of all back-pain cases. The
average compliance was 57% (range 33–94%). Only six
cases were managed with a compliance higher that 70%.
The 28% (n = 29 cases) of back-pain cases placed in the
Specific product category had the lowest average compliance
of 37% (range 10–81%). Only one case was managed with a
compliance higher than 70%.
The most commonly presented type of back pain was that
associated with acute muscle strain (n = 39 cases). Patients
complained of lifting too heavy objects, lifting objects
improperly and imprudent exercising. The second most
common type of back pain was non-specific back pain
(n = 10 cases). In most of these cases the consumer would
have had the pain before, it reoccurred, but the consumer
could not pinpoint the cause of the back pain. In 29% of
cases (n = 30), the pharmacist did not establish the type of
back pain or the circumstances that caused it, mostly cases in
which the consumer presented with a prescription.
A topical analgesic was the most commonly dispensed first-
line treatment, both on its ownor togetherwith anoral analgesic,
usually a combination product. Topical non-steroidal anti-
inflammatory drugs classified as non-prescription items were
the most frequently dispensed agents of all.
Compliance to individual steps in the headache
and back-pain protocol
Average compliance to the steps in the first part of each
protocol – establishing patient identity and nature of symp-
toms –was 43% for the headache protocol (range 7–100%) and
42% for the back-pain protocol (range 4–100%). Average
compliance to the prescription sheet was 48% for the headache
protocol (range 0–100%) and 63% for the back-pain protocol
(range 0–100%). A step with 100% compliance in this section
was one in which the pharmacist was required to explain the
dose and dosage regimen of a prescribed medication. Average
compliance to the steps containing the statements detailing
particular headache or back-pain conditions was 25% for the
headache protocol (range 0–92%) and 23% for the back-pain
protocol (range 0–76%). A step with 0% compliance in
this section was one which requested referral when migraine
symptoms occurred for the first time. Average compliance
to the treatment sheet was 42% for the headache protocol
(range 0–98%) and 33% for the back-pain protocol
(range 0–100%).
Discussion
All outcomes devised for this study were achieved. The main
objective was the development of two protocols which were
well received and generated positive comments from the
participating pharmacists. The assessment of pharmacist
interventions was then carried out through their compliance
with the protocols, rather than through evaluation of patient
outcomes.
The average compliance with which all cases were
managed was 52%. This indicated that there was not an
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acceptable standard of pharmacist involvement in the
management of cases observed. Pharmacists should always
be available to answer questions about medications, be
accessible when advice is sought and give consumers
directions on how to take their medications even when
unsolicited.[24] Cases where pharmacists responded to
symptoms were managed with the highest average compli-
ance followed by cases in which consumers presented at the
pharmacy with a prescription. Cases in which the consumer
asked for a product by name were characterized by the least
interaction between pharmacist and consumer.
It is important to recognize the limitations of the study.
A change in behaviour resulting from awareness of being
observed is termed the Hawthorne effect. This could have led
to the recruited pharmacists performing better than if they
were not being observed. The compliance results might
therefore be overestimated. It was attempted to counteract
this with repeated visits to each pharmacy by the same
observer, so that acute awareness of the presence of the
observer would lessen. Also it was imperative that the
pharmacists’ attention was not drawn to the observer each
time a record was taken since the success of observations has
been identified as depending on how unobtrusively the
observations are performed.[25] Also, the pharmacists were
assured anonymity so that they could feel comfortable
behaving in their usual way. Another issue involved cases
where the consumer asked for a specific product but there
was no interaction between pharmacist and consumer.
Although these were not included in the study, it is
recognized that some of them may have been eligible.
Another limitation was the small number of pharmacists
recruited to take part in the study. This was also reflected in
the small differences in compliance between pharmacists.
Five pharmacists fell into the 41–50% average compliance
range, two in the 51–60% range and three in the 61–70%
range. Only one pharmacist made the 71–80% average
compliance range when dealing with headache cases. None
of the pharmacists had an average compliance higher than
69% when dealing with back-pain cases. However, it was
not the authors’ intention to identify differences between
pharmacists but rather to perform an analysis of the
profession. Undoubtedly, increased numbers of pharmacists
and consumers would benefit the study if it were to be
repeated. At the time of the study ethical approval was not
essential for the data collection required. However, this
varies according to the nature and setting of the study.
The majority of consumers who presented at the
pharmacies with a headache did so to ask for advice or
describe symptoms rather than to purchase a named product
or fill a prescription. In contrast, consumers who presented
with back pain did so mostly to obtain a prescribed product
rather than to ask for advice or for a specific product. The
fact that consumer behaviour varies according to the nature
of the condition has been reported in previous work.[22]
Prescription cases were managed with a low compliance
with the respective protocol, especially considering the
smaller amount of steps that had to be followed with respect
to other categories. By not asking questions about the
patient’s condition pharmacists omit giving timely advice to
patients and reinforcing advice given by other healthcare
professionals.[14] Previous work confirms that interactions
between pharmacists and consumers who obtain treatment on
prescription rarely involve questioning and advice from
pharmacists, and that certain consumers would neither expect
nor want this type of interaction.[26,27]
Specific product cases were managed with the lowest
average compliance with the protocols. A similar finding was
reported by John et al. in their study in Scotland and Wales, to
identify factors affecting pharmacist advice.[21] They con-
cluded that consumers requesting a named product were less
likely to be advised on the use of the product than those who
do not. In fact, pharmacists presume that consumers expect to
make over-the-counter purchases without being questioned[28]
and feel less obligation to give advice to patients who do not
demand it. However, in such cases it is not known whether
consumers may have bought products that were inappropriate
for their condition or less effective than alternatives. A number
of reasons for non-compliance with protocols are reported in
the literature, including a fear of consumers’ resentment to
questioning, a busy pharmacy schedule, time constraints and
previous use of the product by the consumer.[19,29,30]
Both headache and back-pain Describing symptoms cases
were managed with the highest average compliance with the
protocols. This reflected a major effort from pharmacists in
the management of such cases, rather than when consumers
obtained treatment either on prescription or by self-purchase.
The fact that more than a third of cases in this category were
managed with a compliance higher than 70% was considered
as proof of the relevance of the steps included in the
protocols. Morris et al. stated that patients wish to use
pharmacies in the way they desire: they want a pharmacist to
be available to give advice if they perceive it necessary.[28]
Thus, in our study patients who sought advice for the
management of their symptoms got the highest degree of
interaction with the pharmacist. In this scenario pharmacists
followed the protocols and provided a better degree of
intervention as expected by the patients who sought this type
of professional pharmacist advice.
This study adds to our understanding of how pharmacists
respond in relation to presentation of symptoms, requests for
specific products and when presented with a prescription. It
can serve as a benchmark for Maltese pharmacists to improve
their intervention in patient care.
Conclusions
Protocols can be used tomeasure the impact of the intervention
of community pharmacists in patient care. The developed
protocols were found to be applicable to the Maltese
community pharmacy setting. The study results indicate a
lack of pharmacist involvement in the management of cases,
especially caseswhere consumers asked for a product by name.
More emphasis should be placed on the provision of advice to
consumers presenting at the pharmacy.
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